Latest Health News

Alchemy Resources Limited reported a net cash outflow in Q3 2025 but strengthened its financial position by securing $750,000 through a new agreement with Newcam Minerals Ltd.

Rand Mining Ltd has announced a fully franked dividend of 10 cents per share, reinforcing its commitment to regular shareholder returns while maintaining financial prudence.

Tribune Resources has announced a fully franked dividend of 20 cents per share, signalling confidence in its financial position while maintaining cautious discretion for future payouts.

Stelar Metals is actively negotiating new project acquisitions across critical minerals while implementing cost-cutting measures to safeguard its cash position of $2.3 million at the end of September 2025.

Resonance Health reports positive cash flow and significant progress in its clinical trials and Software-as-a-Medical Device business, setting the stage for growth in new international markets.

Ark Mines Ltd reported a significant cash burn in the September quarter, prompting a $500,000 capital raise and plans to secure $4 million from a royalty sale to sustain operations.

Spacetalk Ltd reports robust 28% growth in active mobile subscribers and a 20% rise in annual recurring revenue, fueled by strategic international expansion and a forthcoming software-led platform upgrade.

Associate Global Partners Limited reported a 4.6% increase in funds under management to $1.464 billion for Q3 2025, driven by robust inflows and standout returns from its WCM strategies. The company also sustained positive operating cash flows for the fourth consecutive quarter.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Mont Royal Resources has completed a transformative merger with Commerce Resources, securing A$10 million to advance the Ashram Rare Earths Project, positioning itself as a key player in North America’s critical minerals sector.